Published in final edited form as:

Angew Chem Int Ed Engl. 2011 April 26; 50(18): 4197–4201. doi:10.1002/anie.201007212.

S-Benzimidazolyl Glycosides as a Platform for Oligosaccharide Synthesis by an Active–Latent Strategy**

Scott J. Hasty, Matthew A. Kleine, and Prof. Dr. Alexei V. Demchenko*

Department of Chemistry and Biochemistry, University of Missouri—St. Louis, One University Boulevard, St. Louis, MO 63121 (USA)

Keywords

carbohydrates; glycosides; glycosylation; oligosaccharides; synthetic methods

The involvement of complex carbohydrates in a wide variety of disease-related cellular processes has given this class of natural compounds tremendous diagnostic and therapeutic potential.^[1] While scientists have been able to successfully isolate certain classes of natural carbohydrates, the availability of pure natural isolates is still inadequate to address the challenges offered by modern glycosciences. As a consequence, chemical glycosylation has become a viable means to obtain both natural complex carbohydrates and nonnatural analogues thereof.^[2–4] Unfortunately, chemical synthesis of oligosaccharides of even moderate complexity still remains a considerable challenge, and many more complex structures are not available at all. As such, the development of efficient strategies for oligosaccharide and glycoconjugate synthesis stands out as a demanding area of research.^[5]

As a part of the ongoing research effort in our laboratory to develop versatile methods for chemical glycosylation and expeditious oligosaccharide synthesis, we became interested in glycosyl thioimidates, glycosyl donors equipped with the $SCR^1=NR^2$ leaving group. Among a variety of thioimidates studied by us and others,^[6,7] S-benzoxazolyl (SBox),^[8] and S-thiazolyl (STaz)^[9] moieties were found to be excellent building blocks for oligosaccharide synthesis. We determined that the SBox and STaz glycosides fit into existing progressive strategies for oligosaccharide synthesis, such as selective (including one-pot^[10–12] and solid-phase synthesis),^[13–15] chemoselective (armed–disarmed),^[16–18] and orthogonal^[19–22] strategies. In addition, the glycosyl thioimidates led us to the development of conceptually new strategies for oligosaccharide synthesis: the inverse armed–disarmed strategy,^[23,24] temporary deactivation concept,^[25,26] O2/O5 cooperative effect (superarmed and superdisarmed glycosyl donors),^[17,27–29] coordination-assisted glycosylation,^[30] and surface-tethered iterative carbohydrate synthesis (STICS).^[31]

At the core of the study presented herein is the development of a new method for chemical glycosylation and expeditious oligosaccharide synthesis based on S-benzimidazolyl (SBiz) glycosides. The SBiz moiety was previously investigated as a leaving group for phosphorylation of unprotected glycosyl donors.^[32,33] We envisaged that the SBiz moiety may also be compatible with a very attractive active–latent concept pioneered by Roy,^[34]

**This work was supported by awards from the NIGMS (GM077170), NIAID (AI067494), and AHA (0855743G). Lai-Ping (Pinky) Yan is thanked for the experimental assistance. Dr. Winter and Mr. Kramer (UM—St. Louis) are thanked for HRMS determinations.

© 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

*Fax: (+1)314-516-5342, demchenko@umsl.edu, Homepage: <http://www.umsl.edu/chemistry/faculty/demchenko.htm>.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201007212>.

Fraser-Reid,^[16] Boons,^[35] and more recently further advanced by Kim^[36,37] and others.^[38–40] According to this concept, an active (reactive) leaving group (LG^a) is selectively activated over its latent (unreactive) counterpart (LG^b, Scheme 1). Subsequently, the latent LG^b of the formed disaccharide is converted into the active LG^a. This modification does not involve substitution at the anomeric center like in the two-step activation strategy;^[5] rather it is achieved by a modification of the leaving group, usually at a remote position. We assumed that in the case of the SBiz glycosides, deactivation of the leaving group could be achieved by placing an easily removable protecting group (PG) at the nitrogen atom of the imidazolium ring. The active SBiz leaving group can then be regenerated by simple deprotection as needed.

To pursue this concept we obtained a range of differently protected SBiz glycosides including perbenzylated **1a**, perbenzoylated **1b**, and derivative **1c** equipped with the super-arming protecting-group pattern.^[28] We also obtained the SBiz donor of the D-galacto and D-glucosamino series **1d** and **1e**, respectively. With glycosyl donors **1a–e** in hand, we began evaluating their applicability to chemical glycosidation with standard glycosyl acceptors **2–5**.^[41] Encouragingly, reaction of glycosyl donor **1a** with the primary glycosyl acceptor **2** in the presence of silver(I) triflate completed in 15 min and provided the corresponding disaccharide **6a** in 98% yield (Table 1, entry 1). Copper(II) triflate is a significantly milder promoter for thioimidates, and although a significantly lower reaction rate was observed (60 h) **6a** was isolated in an excellent yield of 93% (Table 1, entry 2). Subsequently, we demonstrated that the SBiz moiety can be efficiently activated under alkylation conditions at elevated temperature, similarly to STaz glycosides.^[22] No significant difference between AlIBr-, BnBr-, or MeI-promoted glycosidations of **1a** was detected, and **6a** was obtained in 84–90% yield (Table 1, entry 3). We noticed a significantly improved α stereoselectivity (up to 5.3:1 with AlIBr) in comparison to that of the metal-assisted glycosylations. Glycosylation of the secondary glycosyl acceptors **3–5** was also proven feasible, and the corresponding disaccharides **7a–9a** were obtained in the presence of AgOTf in 81–95% yield (Table 1, entries 4–6).

Having investigated the reactivity of perbenzylated (armed) glycosyl donor **1a**, we turned our attention to testing its perbenzoylated (disarmed) counterpart **1b**. As anticipated, the reactivity of **1b** was significantly lower than that of **1a**, and only AgOTf-promoted glycosidations were proven to be of preparative value. Thus, the desired disaccharides **6b–9b** were isolated in 84–94% yield (Table 1, entries 7, 10–12). Copper(II) triflate-promoted glycosidation was very slow (144 h; Table 1, entry 8) while alkyl halide-promoted reactions did not proceed at all (Table 1, entry 9). These results suggest that the SBiz glycosides can be applied in accordance with the classic armed–disarmed strategy.^[42] To develop a more flexible route to the synthesis of 1,2-*trans* glycosides we also investigated SBiz glycosyl donor **1c**, which bears the superarming protecting-group pattern.^[28] As expected, AgOTf-promoted glycosidation produced disaccharides **6c–9c** almost instantaneously in 84–98% yield (Table 1, entries 13, 15–17). Also in the presence of Cu(OTf)₂, the reaction rate was significantly higher than that observed with either the armed glycosyl donor **1a** or its disarmed counterpart **1b** (2 h, 93%; Table 1, entry 14).

To broaden the scope of this glycosylation approach, we tested its applicability to the synthesis of D-galactosides and 2-amino-2-deoxyglucosides, highly important and abundant sugar series.^[43–45] Glycosidation of SBiz galactose donor **1d** with glycosyl acceptors **2–5** in the presence of AgOTf proceeded smoothly and the corresponding disaccharides **6d–9d** were obtained in 89–97% yield (Table 1, entries 18–21). Also, glycosidation of *N*-(2,2,2-trichloroethoxy)carbamoyl (*N*-Troc) glycosyl donor **1e** with acceptors **2–5** in the presence of AgOTf was successfully accomplished. The resulting disaccharides **6e–9e** were isolated in 86–94% yields (Table 1, entries 22–25).

Having investigated the applicability of the SBiz glycosides for chemical glycosylation, we next investigated the effects that N-substitution may have on the reactivity of the leaving group. For this purpose, we investigated a variety of N-acyl substituents (acetyl, haloacetyls, benzoyl, substituted benzoyls), and the most prominent results were achieved with the N-anisoylated SBiz building block **10a** obtained from **1a** by reaction with anisoyl chloride in the presence of pyridine (Scheme 2). As projected, no product was formed in glycosidations of **10a** under alkylation conditions (up to 120 h at 55°C). In addition, competitive glycosylation wherein two glycosyl donors (**1a** and **10a**) were allowed to compete for glycosyl acceptor **2** allowed differentiation of the reactivities of SBiz and anisoylated SBiz leaving groups. Thus, the competition experiment in the presence of MeI allowed for nearly complete recovery of the unreacted **10a** (98%), while only traces of **1a** (2%) remained. Less expectedly, AgOTf-promoted activation of the N-anisoylated glycosyl donor **10a** was as efficient as that of its SBiz counterpart **1a** and disaccharide **6a** was rapidly produced (15 min) in 98% yield.

With these promising results, we next began investigating whether SBiz donor **1a** could be selectively activated in the presence the N-anisoylated SBiz acceptor, which represents the key step for executing the SBiz-based active-latent concept. For this purpose we obtained glycosyl acceptor **11** (see the Supporting Information). Very encouragingly, MeI-promoted glycosylation between building blocks **1a** and **11** produced the expected latent disaccharide **12** in 75% yield ($\alpha:\beta = 1:1.8$, Scheme 3). After that, the N-anisoyl group was removed by treatment with NaOMe in MeOH and the resulting active disaccharide **13** was subsequently activated with MeI to afford trisaccharide **14** in 71% yield. This two-step SBiz activation sequence mimics the traditional active-latent concept.^[5]

It should be noted that although the removal of the *N*-anisoyl moiety in **12** with NaOMe/MeOH is suitable for the synthesis of benzylated building blocks, it would represent a hurdle if the application of the active-latent methodology were attempted with acylated compounds. To broaden the scope of this transformation, we investigated other reaction conditions that would not trigger concomitant O-deacylation. As depicted in Scheme 4, we discovered that N-anisoyl in O-benzoylated compound **10b** can be effectively removed in the presence of guanidine in MeOH or, alternatively, tetra-*n*-butylammonium fluoride (TBAF) in THF. No competitive O-benzoyl group removal was detected under these reaction conditions and the desired SBiz donor **1b** was obtained quantitatively. In this context, we anticipate that other acyl groups, for example, 2-(azidomethyl)benzoyl,^[46] 3-(2'-benzyloxyphenyl)-3,3-dimethylpropanoate,^[47] or (2-nitrophenyl)acetyl,^[48] which can be reductively cleaved in the presence of conventional O-acyl substituents (benzoyl), would also be suitable for the purpose of the temporary N-acylation.

Since the N-protected latent SBiz moiety can be activated with a stronger promoter (Scheme 2), we pursued this pathway also. AgOTf-promoted activation of latent disaccharide **12** led to trisaccharide **14** in 84% yield (Scheme 3). By exploring this two-way activation approach we showed that the SBiz moiety serves as a suitable new platform for the active-latent-like activations, but also allows for the direct activation of the latent N-acylated leaving group using stronger promoter.

What remained unknown is why alkylating reagents are able to activate SBiz but not its N-anisoylated counterpart. Based on the anticipation that the SBiz is activated by the direct activation pathway A (Scheme 5) through the anomeric sulfur, like in S-alkyl/aryl^[49] or SBox glycosides,^[22,50] one possible explanation is the electronic effect. It is possible that upon N-anisoylation the sulfur atom in compound **10a** will become too weak a nucleophile to displace the halogen atom of the alkylating reagent. Alternatively, the activation of the SBiz may also take place through the nitrogen atom of the imidazole ring representing the

remote activation pathway B, like in S-pyridyl^[51,52] or STaz^[22] derivatives. In this case, the effect of the N-anisoyl group is steric as it will block the N-activation site of the SBiz moiety.

To differentiate the two pathways we set up a model experiment wherein SBiz donor **1a** reacted with 2-propanol in the presence of BnBr (Scheme 5). Upon completion of the reaction, judged by the disappearance of **1a** and formation of **16**,^[53] we separated and analyzed all components of the reaction mixture. 2-Benzylsulfanyl-1*H*-benzimidazole **15**^[54,55] was isolated and its identity was proven by spectral and X-ray methods, whereas no trace of its N-benzylated counterpart **17**^[56,57] was detected. The result of this study indicates that activation of SBiz under alkylation conditions takes place through the sulfur atom, similarly to that found previously for SBox glycosides.^[22,50] Therefore, we conclude that the deactivation effect of the N-anisoyl moiety in **10a** is electronic. However, whether this effect results from simple electron withdrawal or distortion of the aromaticity of the imidazole ring is yet to be determined. What makes this disarming effect different from the well-documented disarming effect in glycosylation^[42] is that herein the disarming is achieved by acylation of the leaving group, not by introducing the neighboring acyl substituents in the sugar moiety.

In conclusion, we have investigated the S-benzimidazolyl (SBiz) anomeric moiety as a new leaving group that can be activated for chemical glycosylation under a variety of conditions including metal-assisted and alkylation pathways. Differentiation between the two possible reaction pathways for activation of the SBiz moiety was achieved by an extended mechanistic study. We also demonstrated that the application of the substituted SBiz moiety allows execution of rapid oligosaccharide assembly through active-latent- and armed-disarmed-like concepts.

Experimental Section

1a: A solution of ethyl 2,3,4,6-tetra-*O*-benzyl-1-thio- β -D-glucopyranoside^[58] (2.19 g, 3.75 mmol) and activated molecular sieves (3 Å, 1.88 g) in CH₂Cl₂ (56 mL) was stirred under argon for 1 h at room temperature. A freshly prepared solution of Br₂ in CH₂Cl₂ (36 mL, 1:165, v/v) was then added and the reaction mixture was stirred for 5 min at room temperature. After that, the solid was isolated by filtration and the filtrate was concentrated in vacuo at room temperature. The crude residue was dissolved in dry MeCN (80 mL) and KSBiz (1.76 g, 9.36 mmol) and [18]crown-6 (0.20 g, 0.75 mmol) were added. The resulting reaction mixture was stirred under argon for 16 h at room temperature. The solid was then isolated by filtration and the filtrate was concentrated in vacuo. The residue was diluted with CH₂Cl₂ (200 mL) and washed successively with 10% aq. NaOH (20 mL) and water (3 $\times$ 20 mL). The organic layer was separated, dried with MgSO₄, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate/toluene gradient elution) to afford compound **1a** (1.85 g, 73%) as an off-white foam. *R*_f = 0.54 (ethyl acetate/toluene, 3:17, v/v); [α]_D²⁸ = -28.7° (*c* = 1.0, CHCl₃); ¹H NMR: δ = 3.45 (dd, 1H, *J*_{2,3} = 8.5 Hz; H-2), 3.58–3.82 (m, 5H; H-3, 4, 5, 6a, 6b), 4.57 (dd, 2H, *J*² = 11.5 Hz; CH₂Ph), 4.64 (dd, 2H, *J*² = 11.1 Hz; CH₂Ph), 4.76 (d, 1H, *J*_{1,2} = 9.6 Hz; H-1), 4.76 (dd, 2H, *J*² = 10.0 Hz; CH₂Ph), 4.82 (dd, 2H, *J*² = 10.9 Hz; CH₂Ph), 6.38–7.38 ppm (m, 25H; aromatic, NH); ¹³C NMR: δ = 68.8, 74.0, 75.3, 75.8, 76.0, 77.2, 78.3, 80.9, 84.1, 86.0, 122.5, 127.9 ($\times$ 3), 128.1 ($\times$ 4), 128.4, 128.5 ($\times$ 3), 128.6 ($\times$ 10), 128.9 ($\times$ 3), 129.0, 137.4, 137.5, 137.7, 138.1, 146.5 ppm; HR-FAB MS: *m/z* calcd for C₄₁H₄₁N₂O₅S: 673.2736 [*M*+H]⁺; found: 673.2732.

10: Anisoyl chloride (0.58 mL, 4.29 mmol) was added dropwise to a stirred solution of **1a** (0.962 g, 1.4 mmol) in pyridine (10 mL). The resulting reaction mixture was stirred under argon for 15 min at room temperature. After that, the volatiles were removed in vacuo and

the residue was co-evaporated with toluene (3 × 10 mL). The residue was diluted with CH₂Cl₂ (200 mL), and washed with water (20 mL), 1N aq. HCl (20 mL), water (20 mL), sat. aq. NaHCO₃ (2 × 20 mL), and water (3 × 10 mL). The organic phase was separated, dried over MgSO₄, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate/toluene gradient elution) to afford compound **10** (1.05 g, 91%) as an off-white foam. *R*_f = 0.50 (ethyl acetate/toluene, 1:9, v/v);

$[\alpha]_D^{27} = +119.5^\circ$ (*c* = 1.0, CHCl₃); ¹H NMR: δ = 3.66 (dd, 1H, *J*_{2,3} = 8.67 Hz; H-2), 3.70–3.87 (m, 5H; H-3, 4, 5, 6a, 6b), 3.88 (s, 3H; OCH₃), 4.54 (dd, 2H, *J*² = 11.9 Hz; CH₂Ph), 4.71 (dd, 2H, *J*² = 10.7 Hz; CH₂Ph), 4.87 (dd, 2H, *J*² = 10.7 Hz; CH₂Ph), 4.88 (dd, 2H, *J*² = 10.9 Hz; CH₂Ph), 5.83 (d, 1H, *J*_{1,2} = 10.2 Hz; H-1), 6.89–7.71 ppm (m, 28H; aromatic); ¹³C NMR: δ = 55.8, 68.8, 73.5, 75.1, 75.5, 75.9, 77.9, 79.6, 81.2, 85.1, 86.9, 113.4, 114.4 (× 3), 119.3, 123.4, 124.2, 124.9, 127.7, 127.9 (× 3), 128.0 (× 7), 128.5 (× 3), 128.6 (× 4), 129.2, 132.8 (× 2), 134.7, 138.1, 138.3 (× 2), 138.6, 143.9, 151.8, 164.5, 167.3 ppm; HR-FAB MS: *m/z* calcd for C₄₉H₄₇N₂O₇S: 807.3104 [*M*+H]⁺; found: 807.3081.

Typical AgOTf-promoted glycosylation procedure: A mixture of glycosyl donor (0.045 mmol), glycosyl acceptor (0.030 mmol), and freshly activated molecular sieves (3 Å, 125 mg) in 1,2-dichloroethane (1 mL) was stirred under argon for 1 h. AgOTf (0.090 mmol) was added and the reaction mixture was monitored by TLC. Upon completion (see Table 1), the solid was isolated by filtration and the filtrate was diluted with CH₂Cl₂ (15 mL), and washed with 5% aq NaOH (5 mL) and water (3 × 5 mL). The organic layer was separated, dried with MgSO₄, and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate/toluene gradient elution) to afford the corresponding oligosaccharide.

Typical alkyl halide-promoted glycosylation procedure: A mixture of glycosyl donor (0.045 mmol), glycosyl acceptor (0.030 mmol), and freshly activated molecular sieves (4 Å, 125 mg) in 1,2-dichloroethane (1 mL) was stirred under argon for 1 h. Alkyl halide (0.027 mmol) was added and the reaction mixture was monitored by TLC. Upon completion (see Table 1), the solid was isolated by filtration and the filtrate was diluted with CH₂Cl₂ (15 mL), and washed with 5% aq NaOH (5 mL) and water (3 × 5 mL). The organic layer was separated, dried with MgSO₄, and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate/toluene gradient elution) to afford the corresponding disaccharide.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Varki, A.; Cummings, RD.; Esko, JD.; Freeze, HH.; Bertozzi, CR.; Stanley, P.; Hart, GW.; Etzler, ME. *Essentials of Glycobiology*. 2. CSH Laboratory Press; New York: 2009.
2. Demchenko, AV. *Handbook of Chemical Glycosylation*. Demchenko, AV., editor. Wiley-VCH; Weinheim: 2008. p. 1
3. Zhu X, Schmidt RR. *Angew Chem*. 2009; 121:1932. *Angew Chem Int Ed*. 2009; 48:1900.
4. Boltje TJ, Buskas T, Boons GJ. *Nat Chem*. 2009; 1:611. [PubMed: 20161474]
5. Smoot JT, Demchenko AV. *Adv Carbohydr Chem Biochem*. 2009; 62:161. [PubMed: 19501706]
6. Ramakrishnan A, Pornsuriyasak P, Demchenko AV. *J Carbohydr Chem*. 2005; 24:649.
7. Szeja, W.; Gryniewicz, G. *Handbook of Chemical Glycosylation*. Demchenko, AV., editor. Wiley-VCH; Weinheim: 2008. p. 329
8. Demchenko AV, Malysheva NN, De Meo C. *Org Lett*. 2003; 5:455. [PubMed: 12583742]

9. Demchenko AV, Pornsuriyasak P, De Meo C, Malysheva NN. *Angew Chem*. 2004; 116:3131. *Angew Chem Int Ed*. 2004; 43:3069.
10. Wang Y, Ye XS, Zhang LH. *Org Biomol Chem*. 2007; 5:2189. [PubMed: 17609746]
11. Pornsuriyasak P, Demchenko AV. *Tetrahedron: Asymmetry*. 2005; 16:433.
12. Parameswar, AR.; Demchenko, AV. *Progress in the Synthesis of Complex Carbohydrate Chains of Plant and Microbial Polysaccharides*. Nifantiev, NE., editor. Transworld Research Network; Kerala: 2009. p. 463
13. Seeberger PH, Haase WC. *Chem Rev*. 2000; 100:4349. [PubMed: 11749351]
14. Schmidt, RR.; Jonke, S.; Liu, K. *ACS Symp Ser (Frontiers in Modern Carbohydrate Chemistry)*. Demchenko, AV., editor. Vol. 960. Oxford University Press; 2007. p. 209
15. Parlato MC, Kamat MN, Wang H, Stine KJ, Demchenko AV. *J Org Chem*. 2008; 73:1716. [PubMed: 18237185]
16. Fraser-Reid B, Udodong UE, Wu ZF, Ottosson H, Merritt JR, Rao CS, Roberts C, Madsen R. *Synlett*. 1992; 927
17. Kamat MN, Demchenko AV. *Org Lett*. 2005; 7:3215. [PubMed: 16018624]
18. Bongat AFG, Kamat MN, Demchenko AV. *J Org Chem*. 2007; 72:1480. [PubMed: 17253751]
19. Kanie O, Ito Y, Ogawa T. *J Am Chem Soc*. 1994; 116:12073.
20. Pornsuriyasak P, Demchenko AV. *Chem Eur J*. 2006; 12:6630.
21. Vidadala SR, Thadke SA, Hotha S. *J Org Chem*. 2009; 74:9233. [PubMed: 19886637]
22. Kaeothip S, Pornsuriyasak P, Rath NP, Demchenko AV. *Org Lett*. 2009; 11:799. [PubMed: 19161321]
23. Smoot JT, Pornsuriyasak P, Demchenko AV. *Angew Chem*. 2005; 117:7285. *Angew Chem Int Ed*. 2005; 44:7123.
24. Smoot JT, Demchenko AV. *J Org Chem*. 2008; 73:8838. [PubMed: 18939875]
25. Pornsuriyasak P, Gangadharmath UB, Rath NP, Demchenko AV. *Org Lett*. 2004; 6:4515. [PubMed: 15548064]
26. Pornsuriyasak P, Rath NP, Demchenko AV. *Chem Commun*. 2008:5633.
27. Mydock LK, Demchenko AV. *Org Lett*. 2008; 10:2107. [PubMed: 18447362]
28. Mydock LK, Demchenko AV. *Org Lett*. 2008; 10:2103. [PubMed: 18447363]
29. Premathilake HD, Mydock LK, Demchenko AV. *J Org Chem*. 2010; 75:1095. [PubMed: 20104917]
30. Pornsuriyasak P, Vetter C, Kaeothip S, Kovermann M, Balbach J, Steinborn D, Demchenko AV. *Chem Commun*. 2009:6379.
31. Pornsuriyasak P, Ranade SC, Li A, Parlato MC, Sims CR, Shulga OV, Stine KJ, Demchenko AV. *Chem Commun*. 2009:1834.
32. Ferri7res V, Blanchard S, Fischer D, Plusquellec D. *Bioorg Med Chem Lett*. 2002; 12:3515. [PubMed: 12443765]
33. Euzen R, Ferrieres V, Plusquellec D. *J Org Chem*. 2005; 70:847. [PubMed: 15675842]
34. Roy R, Andersson FO, Letellier M. *Tetrahedron Lett*. 1992; 33:6053.
35. Boons GJ, Isles S. *Tetrahedron Lett*. 1994; 35:3593.
36. Kim KS, Kim JH, Lee YJ, Lee YJ, Park J. *J Am Chem Soc*. 2001; 123:8477. [PubMed: 11525654]
37. Kim, KS.; Jeon, HB. *Handbook of Chemical Glycosylation*. Demchenko, AV., editor. Wiley-VCH; Weinheim: 2008. p. 185
38. Hinklin RJ, Kiessling LL. *J Am Chem Soc*. 2001; 123:3379. [PubMed: 11457079]
39. Huang L, Wang Z, Huang X. *Chem Commun*. 2004:1960.
40. Wang P, Haldar P, Wang Y, Hu H. *J Org Chem*. 2007; 72:5870. [PubMed: 17580902]
41. Ranade SC, Kaeothip S, Demchenko AV. *Org Lett*. 2010; 12:5628. [PubMed: 21087037]
42. Fraser-Reid B, Wu Z, Udodong UE, Ottosson H. *J Org Chem*. 1990; 55:6068.
43. Varki A. *Glycobiology*. 1993; 3:97. [PubMed: 8490246]
44. Bongat AFG, Demchenko AV. *Carbohydr Res*. 2007; 342:374. [PubMed: 17125757]

45. Robyt, JE. Glycoscience: Chemistry and Chemical Biology. Fraser-Reid, B.; Tatsuta, K.; Thiem, J., editors. Vol. 1. Springer; Berlin: 2001. p. 75
46. Xu J, Guo Z. Carbohydr Res. 2002; 337:87. [PubMed: 11814439]
47. Crich D, Cai F. Org Lett. 2007; 9:1613. [PubMed: 17346061]
48. Daragics K, F4gedi P. Org Lett. 2010; 12:2076. [PubMed: 20361745]
49. Zhong, W.; Boons, GJ. Handbook of Chemical Glycosylation. Demchenko, AV., editor. Wiley-VCH; Weinheim: 2008. p. 261
50. Kamat MN, Rath NP, Demchenko AV. J Org Chem. 2007; 72:6938. [PubMed: 17676918]
51. Hanessian S, Bacquet C, Lehong N. Carbohydr Res. 1980; 80:C17.
52. Mereyala HB, Reddy GV. Tetrahedron. 1991; 47:6435.
53. Briner K, Vasella A. Helv Chim Acta. 1989; 72:1371.
54. Kumar RV, Gopal KR, Kumar KVSRS. J Heterocycl Chem. 2005; 42:1405.
55. Yavo EA, Kakou-Yao R, Coulibaly S, Abou A, Tenon AJ. Acta Crystallogr Sect E. 2007; 63:o4551.
56. Lee TR, Kim K. J Heterocycl Chem. 1989; 26:747.
57. Kruse LI, Kaiser C, DeWolf WE, Finkelstein JA, Frazee JS, Hilbert EL, Ross ST, Flaim KE, Sawyer JL. J Med Chem. 1990; 33:781. [PubMed: 2299645]
58. Andersson F, Fugedi P, Garegg PJ, Nashed M. Tetrahedron Lett. 1986; 27:3919.

Scheme 1.

Outline of the active-latent strategy and the SBiz leaving group explored in this work.

Scheme 2.

Synthesis and glycosidation of N-anisoylated glycosyl donor **10a**; competition experiment with SBiz donor **1a**. 1,2-DCE= 1,2-dichloroethane.

Scheme 3.

Activation of SBiz donor **1a** over N-anisoylated SBiz acceptor **11** in the active-latent fashion.

Scheme 4.

Removal of the N-anisoyl group in the presence of the O-benzoyl group. Conditions: a) 0.5M guanidine/MeOH (0.5 equiv) in CH₂Cl₂/MeOH (9:1, v/v), RT, 5 min; b) 2 equiv 1 M TBAF/THF in THF, RT, 3 h; quantitative yield of **1b** in both procedures.

Scheme 5.

Direct pathway A versus remote pathway B for SBiz activation.

Table 1

Glycosidation of SBiz glycosyl donors **1a–e** with glycosyl acceptors **2–5**.

Entry	Donor + acceptor	Promoter ^[a]	<i>t</i>	Product (yield, α/β ratio)
1	1a+2	AgOTf	15 min	6a (98%, 1.1:1)
2	1a+2	Cu(OTf) ₂	60 h	6a (93%, 1.3:1)
3	1a+2	AllBr, BnBr MeI (55°C) ^[b]	12 h	6a (84–90%, 3.3–5.3:1)
4	1a+3	AgOTf	15 min	7a (81%, 1.8:1)
5	1a+4	AgOTf	15 min	8a (91%, 1.3:1)
6	1a+5	AgOTf	15 min	9a (95%, 1.6:1)
7	1b+2	AgOTf	2 h	6b (86%, β only)
8	1b+2	Cu(OTf) ₂	144 h	6b (83%, β only)
9	1b+2	AllBr, BnBr MeI (55°C)	120 h	no reaction
10	1b+3	AgOTf	45 min	7b (94%, β only)
11	1b+4	AgOTf	2 h	8b (87%, β only)
12	1b+5	AgOTf	2 h	9b (84%, β only)
13	1c+2	AgOTf	<5 min	6c (98%, β only)
14	1c+2	Cu(OTf) ₂	2 h	6c (93%, β only)
15	1c+3	AgOTf	<5 min	7c (84%, β only)
16	1c+4	AgOTf	<5 min	8c (90%, β only)
17	1c+5	AgOTf	<5 min	9c (88%, β only)
18	1d+2	AgOTf	2 h	6d (97%, β only)
19	1d+3	AgOTf	2 h	7d (94%, β only)
20	1d+4	AgOTf	3 h	8d (89%, β only)
21	1d+5	AgOTf	3.5 h	9d (89%, β only)
22	1e+2	AgOTf	30 min	6e (94%, β only)
23	1e+3	AgOTf	30 min	7e (92%, β only)
24	1e+4	AgOTf	30 min	8e (86%, β only)
25	1e+5	AgOTf	30 min	9e (92%, β only)

^[a] Performed in the presence of 3 Å molecular sieves at room temperature, unless noted otherwise.

^[b] Reaction at room temperature was much more sluggish. Bn =benzyl, Bz =benzoyl, Tf =triflate, All =allyl.